公司资料
DexCom, Inc. 股价、新闻与催化剂
- 股票代码:
- DXCM
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
88.76 USD (-1.10%)
收盘价
最后更新: 2026年8月17日
28.3B USD
市值
股价为何变动
As of Aug 17, 2026, DXCM closed down 1.10% at $88.76. No new same-company headline was identified in the current news window.
公司概览
业务概览
DexCom is a leading medical technology company focused on continuous glucose monitoring for diabetes care. The company’s platform is built around connected sensors, recurring usage, and the expansion of CGM across broader patient populations.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, DexCom is a healthcare technology company with strong exposure to diabetes monitoring. It sits in device-driven chronic care rather than drug development.
商业模式特征
DexCom generates revenue through sensor sales, platform adoption, and recurring glucose-monitoring usage. Investors track user growth, reimbursement, product launches, and whether the company can keep extending CGM beyond its core base.
生物医药行业定位
DexCom is not biotech proper, but it is one of the most important diabetes technology names in healthcare. It is more about device adoption and recurring use than binary clinical or FDA-drug events.
未来催化剂
- Dexcom’s watchlist is G7 adoption, international expansion, and sensor-cycle execution that supports recurring revenue. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。